Search clinical trials for: PRX302

Total 20 results

Sophiris Bio Corp

Completed

An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy

Locally Recurrent Prostate Cancer

United States
Sophiris Bio Corp

Completed

Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer

Prostate Cancer

United Kingdom, United States
Sophiris Bio Corp

Completed

Transperineal Intraprostatic Injection of PRX302 Under Ultrasound Guidance for Management of Prostatic Hyperplasia (TRIUMPH-1)

Benign Prostatic Hyperplasia

Canada
Sophiris Bio Corp

Completed

Evaluate, Safety and Tolerability of Intraprostatic PRX302 Administration, Low to Intermediate Risk Prostate Cancer

Prostate Cancer

United Kingdom
Sophiris Bio Corp

Completed

Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)

Benign Prostatic Hyperplasia

United States
Sophiris Bio Corp

Completed

Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH (PLUS-1)

Benign Prostatic Hyperplasia

United States, Australia, Canada, Russian Federation, Ukraine, New Zealand
Sophiris Bio Corp

Completed

PSA-Activated PSA-PAH1 for Locally Recurrent Prostate Cancer

Prostate Cancer

United States
Prothena Biosciences Limited
Hoffmann-La Roche

Completed

Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease

Parkinson's Disease

United States
Prothena Biosciences Limited
Hoffmann-La Roche

Completed

Single Ascending Dose Study of PRX002 in Healthy Subjects

Parkinson's Disease

United States
Hoffmann-La Roche
Prothena Biosciences Limited

Active, not recruiting

A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease (PASADENA)

Parkinson's Disease

United States, Spain, France, Germany, Austria
Prothena Biosciences Limited

Terminated

A Study of PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis

Amyloidogenic Transthyretin (ATTR) Amyloidosis

United States, Spain, Sweden, Portugal
Prothena Biosciences Limited

Completed

Multiple Ascending Dose Study of PRX003 in Subjects With Psoriasis

Psoriasis

United States
Prothena Biosciences Limited

Completed

Single Ascending Dose Study of PRX003 in Healthy Subjects

Psoriasis

United States
Sophiris Bio Corp

Withdrawn

Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1) (CLARITY-1)

Glioblastoma Multiforme
Arcellx, Inc.

Recruiting

Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Duke University
Genzyme, a Sanofi Company

Recruiting

High Dose Inspiratory Muscle Training in LOPD

Late-Onset Pompe Disease | Lysosomal Disease

United States
Novartis Pharmaceuticals

Completed

Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma

Metastatic Renal Cell Carcinoma | Metastatic Melanoma

United States
Peptron, Inc.

Completed

A Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of Sustained Release(SR) Exenatide

Type 2 Diabetes Mellitus

Korea, Republic of
Tong Lee
National Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)

Completed

PHASE IIA: Trial of a Novel Ondansetron Formulation (OND-PR002) and Immediate-Release Methylphenidate (Ritalin®)(OND003IND)

Cocaine Dependence | Methamphetamine Dependence

United States
Soligenix

Recruiting

Topical SGX302 for Mild-to-Moderate Psoriasis

Psoriasis | Plaque Psoriasis | Psoriasis Vulgaris

United States

Search clinical trials for: PRX302

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belgium

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations